Meridian Bioscience, a fully integrated life science company, has received the FDA clearance for a new test for Campylobacter. Launched as Premier Campy, the rapid enzyme immunoassay test provides for optimized detection of Campylobacter infection, the company said.
According to the company, there is a significant need for the Premier Campy test because
BioMed Central has published the abstract of a study into the character of Campylobacter isolates from infected children in northen Taiwan, as well as basic information about the patients, collected from December 2003 to February 2005.